Credit Suisse Double Downgrades Edge Therapeutics (EDGE) to Underperform
Tweet
Share
E-mailGet Alerts EDGE Hot Sheet
Price: $51.78 -0.31%
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
2 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Credit Suisse downgraded Edge Therapeutics (NASDAQ: EDGE) from Outperform to Underperform with a price target of $1.00 (from $17.00).
For an analyst ratings summary and ratings history on Edge Therapeutics click here. For more ratings news on Edge Therapeutics click here.
Shares of Edge Therapeutics closed at $1.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marvell (MRVL) PT Raised to $225 at TD Cowen
- CrowdStrike (CRWD) PT Raised to $250 at Benchmark Ahead of Q2 Results
- Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
